Hoche Partners Amends Procaps Group Stake Disclosure

TL;DR

**Hoche Partners just updated their Procaps Group ownership filing, signaling a change in their stake.**

AI Summary

Hoche Partners Pharma Holding S.A. filed an amendment to their Schedule 13D on January 12, 2024, regarding their ownership in Procaps Group, S.A. This filing, an Amendment No. 1, updates previous disclosures about their stake in Procaps Group's Ordinary Shares, nominal value of $0.01 per share. This matters to investors because it signals a change in the reporting person's previously disclosed ownership or intentions, which could influence market perception or future strategic moves for Procaps Group.

Why It Matters

This filing indicates an update to a significant shareholder's position or intentions, which can impact investor sentiment and potentially the stock's future direction.

Risk Assessment

Risk Level: medium — While not inherently negative, any change in a major shareholder's disclosure can introduce uncertainty or signal potential shifts in corporate control or strategy.

Analyst Insight

An investor should monitor subsequent filings from Hoche Partners Pharma Holding S.A. to understand the specific changes in their ownership or intentions, as this amendment itself does not detail the nature of the change.

Key Players & Entities

• Hoche Partners Pharma Holding S.A. (company) — the entity filing the SC 13D/A amendment
• Procaps Group, S.A. (company) — the subject company whose securities are being reported
• $0.01 (dollar_amount) — nominal value per Ordinary Share of Procaps Group, S.A.
• January 12, 2024 (date) — the date of the event requiring the filing of this statement

FAQ

Key Financial Figures

• $0.01 — er) Ordinary Shares, nominal value of $0.01 per share (Title of Class of Securiti

Filing Documents

• procaps_13da1.htm (SC 13D/A) — 48KB
• ex99_7.htm (EX-99.7) — 13KB
• ex99_8.htm (EX-99.8) — 15KB
• image_001.jpg (GRAPHIC) — 13KB
• image_002.jpg (GRAPHIC) — 5KB
• 0001019056-24-000022.txt ( ) — 102KB

From the Filing

SC 13D/A 1 procaps_13da1.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Procaps Group, S.A. (Name of Issuer) Ordinary Shares, nominal value of $0.01 per share (Title of Class of Securities) L7756P 102 (Ordinary Shares) (CUSIP Number) 9 rue de Bitbourg, L-1273 Luxembourg Grand Duchy of Luxembourg R.C.S. Luxembourg: B253360 Tel : +356 7995-6138 (Address of Principal Executive Offices) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 12, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o . Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Hoche Partners Pharma Holding S.A. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o 3. SEC USE ONLY 4. SOURCE OF FUNDS (See Instructions) AF 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o 6. CITIZENSHIP OR PLACE OF ORGANIZATION Grand Duchy of Luxembourg NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7. SOLE VOTING POWER 15,877,516 8. SHARED VOTING POWER 0 9. SOLE DISPOSITIVE POWER 15,877,516 10. SHARED DISPOSITIVE POWER 0 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,877,516 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) o 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.1% 14. TYPE OF REPORTING PERSON (See Instructions) CO Explanatory Note: This Amendment No. 1 (“ Amendment No. 1 ”) amends and supplements the statement on Schedule 13D of Hoche Partners Pharma Holding S.A. (the “ Reporting Person ”) that was filed with the Securities and Exchange Commission on September 29, 2021 (the “ Schedule 13D ”) with respect to the ordinary shares, nominal value of $0.01 per share, of Procaps Group, S.A., (the “ Issuer ” or “ Procaps ”). This amendment to the Schedule 13D constitutes Amendment No. 1 to the Schedule 13D. Capitalized terms used but not defined herein have the meanings given to such terms in the Schedule 13D. This Amendment No. 1 is being filed for the purpose of publicly disclosing certain important developments in connection with the Reporting Person’s investment in Procaps. Except as set forth herein, the Schedule 13D is unmodified. Item 1. Security and Issuer. Item 1 of the Schedule 13D is amended and restated in its entirety to read as follows: This (the “ Ordinary Shares ”), of Procaps Group, S.A., a public limited liability company ( société anonyme ) governed by the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg, and registered with the Luxembourg Trade and Companies’ Register ( Registre de Commerce et des Sociétés, Luxembourg ) under number B 253360 (the “ Issuer ”). Item 2. Identity and Background. Item 2 of the Schedule 13D is amended as follows: (a) The present principal business of the Reporting Person is to hold the securities of the Issuer, as described in this Statement. Item 3. Purpose of the Transaction Item 4 of the Schedule 13D is amended and supplemented as follows: On January 19, 2023, Mr. Alejandro Weinstein resigned from the Board of Directors (the “ Board ”) of the Issuer, effective immediately. In connection with Mr. Weinstein’s resignation, Mr. Weinstein also resigned from his position as a member and Chairman of the M&A Committee of the Board. Mr. Weinstein’s resignation from the Board was aligned with the period for his service as a director pr

View Full Filing

View this SC 13D/A filing on SEC EDGAR